| 1 |
27593256 | Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma. | 2016 |
1 |
| 2 |
25596049 | [Cancer therapy using unsealed radioisotopes-the present and future]. | 2014 Dec |
1 |
| 3 |
23158095 | A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. | 2012 Dec |
1 |
| 4 |
17287964 | [Therapy of follicular lymphoma]. | 2007 Apr |
1 |
| 5 |
16540013 | [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status]. | 2006 Jan-Feb |
1 |
| 6 |
16091197 | New developments in immunotherapy for non-Hodgkin's lymphoma. | 2005 Sep |
1 |
| 7 |
16203814 | Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. | 2005 Oct 1 |
1 |
| 8 |
16304400 | Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. | 2005 |
1 |
| 9 |
15045033 | Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. | 2004 Feb |
1 |
| 10 |
15453924 | Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. | 2004 Sep |
1 |
| 11 |
15498146 | Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. | 2004 Oct |
1 |
| 12 |
12663713 | Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. | 2003 Apr 1 |
1 |
| 13 |
12837157 | Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. | 2003 Jun |
1 |
| 14 |
11877757 | Choosing an optimal radioimmunotherapy dose for clinical response. | 2002 Feb 15 |
1 |
| 15 |
11258413 | Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma. | 2001 Feb |
1 |
| 16 |
11587375 | Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. | 2001 Aug |
1 |
| 17 |
11762415 | Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. | 2001 Dec |
1 |
| 18 |
10561019 | Radiolabeled antibody therapy of B-cell lymphomas. | 1999 Oct |
1 |
| 19 |
9816191 | Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. | 1996 Mar |
1 |